Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 842 across all filing types
Latest filing 2025-03-20 Capital/Financing Update
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - BXN 5 pages 18.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed issue of new securities by BIOXYNE LIMITED. It includes specifics about the number and type of securities, issue date, conditions, and compliance with ASX Listing Rules. The content focuses on the announcement of a placement or other type of securities issue, including terms and conditions, but does not contain financial statements or performance data. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising or capital structure changes. The document is not a full financial report, earnings release, or regulatory filing, but a detailed announcement of a securities issuance.
2025-03-20 English
Proposed issue of securities - BXN 5 pages 18.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed issue of new securities by BIOXYNE LIMITED. It includes specifics about the type of securities (unlisted options), the number to be issued, the issue date, and the consideration for the issue (advisory services). The document is a formal announcement to the ASX regarding a placement or other type of issue of securities. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is clearly an announcement about capital raising activity and changes in capital structure. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (6467 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2025-03-20 English
Pause in Trading 1 page 116.1KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It is dated and issued by ASX Listings Compliance. There is no financial data, report content, or detailed information about financial performance or corporate actions. The document is an announcement related to trading status, not a report or detailed filing. Given its brevity and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2025-03-18 English
Trading Halt 2 pages 229.3KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Bioxyne Limited regarding a trading halt requested pending a capital raising announcement. It references a trading halt under ASX listing rules and states the halt will last until an announcement about the capital raising is made or a specified date. There is no financial data, report content, or detailed analysis present. The document is short (1887 characters) and serves as a notification about a trading halt related to capital raising activities, not the capital raising announcement itself or a financial report. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes.
2025-03-18 English
Bioxyne Investor Webinar 5 March 3 pages 265.4KB
Investor Presentation Classification · 95% confidence The document is an announcement dated 4 March 2025 inviting shareholders and prospective investors to an online investor webinar scheduled for 5 March 2025. It includes details about the event, the presenter (Managing Director), registration link, and company background information. There is no substantive financial data, financial statements, or detailed analysis of financial results. The document is primarily an invitation and update about an upcoming investor presentation event, not the presentation itself or a financial report. Therefore, it fits the category of an Investor Presentation (IP) announcement or invitation rather than a full report or earnings release. Given the nature of the content, the best classification is Investor Presentation (IP).
2025-03-03 English
Half Yearly Report and Accounts 31 pages 2.4MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D – Half Year Report' and covers the half year ended 31 December 2024, with detailed financial statements including Statement of Profit or Loss, Statement of Financial Position, and Notes to the Financial Statements. It includes a Directors' Report, Auditor's Independence Declaration, and an Independent Auditor's Review Report. The content is comprehensive and contains actual financial data and analysis for a period shorter than a full fiscal year. The document is 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of detailed financial statements and management discussion confirms it is an Interim / Quarterly Report. H1 2025
2025-02-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.